RE:RE:It's not NailoserI have no idea whether the share prices would fall or increase based on the 2021 results. And for me, I wouldn't focus on Aristotle sales. Before the Care acquisition, it would make perfect sense. But now, if the 'new' company is as vertically integrated as we are told, and it does offer so much more, it would not be that meaningful to solely focus on Aristotle sales. So for me, the test would be to see growth in total revenues.
The 2021 Q3 financials shows both lab testing revenues and clinical consultation revenues. First, the clinical consultation revenues, at least to me, appears to be 1 month of revenues generated by Care (acquisition closed Sept 2, 2021). So if this revenue stream increases four fold for Dec 2021, then it would be going in the right direction. Anything less than 4 times would personally be disappointing. Any more would be a nice surprise.
Secondly, it would be nice to see lab testing revenues increase by another $1m from the $3.3m reported in Q3. A $1m increase here, while lower than I would like, indicates to me that there were some level of Aristotle sales, as I expect a steep drop in Covid testing during Q4.
TL;DR, if StageZero reports total revenues of approx. $5.5m for 2021, I would be happy.
TrippinAgain123 wrote: If Aristotle revenue ends up being like 60k (which is possible) and overall revenue is flat or even falling on the next financials I would begin to start thinking about a class action and gathering enough people together for it because it will be the total end of the share price for 2022....